Triple-Negative Breast Cancer: Early Assessment with ^{18}F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse

David Groheux[1,2], Elif Hindié[1,2], Sylvie Giacchetti[3], Marc Delord[4], Anne-Sophie Hamy[3], Anne de Roquancourt[5], Laetitia Vercellino[1], Nathalie Berenger[1], Michel Marty[3,6], and Marc Espié[3]

[1]Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France; [2]B2T, Doctoral School, IUH, University of Paris VII, Paris, France; [3]Breast Diseases Unit, Department of Medical Oncology, Saint-Louis Hospital, Paris, France; [4]Department of Biostatistics and Bioinformatics, Institut Universitaire d'Hématologie, Paris, France; [5]Department of Pathology, Saint-Louis Hospital, Paris, France; and [6]Centre for Therapeutic Innovation, Saint Louis University Hospital, Paris, France

Triple-negative breast cancer, an aggressive subtype, represents 15% of invasive breast tumors. This prospective study investigated whether early changes in ^{18}F-FDG tumor uptake during neoadjuvant chemotherapy (NAC) can predict outcomes. **Methods:** Twenty (M0) patients underwent ^{18}F-FDG PET/CT at baseline and after the second cycle. NAC was continued irrespective of PET results. **Results:** At surgery, 6 patients had a pathologic complete response, whereas 14 had residual tumor. Four patients showed early relapse (in the 2 y after surgery). There were 11 metabolic responders and 9 nonresponders using a 42% decrease in maximum standardized uptake value as a cutoff. In nonresponding patients, the risk of residual tumor at surgery was 100% (vs. 45% in responders; $P = 0.014$), and the risk of early relapse was 44% (vs. 0%; $P = 0.024$). **Conclusion:** A less than 42% decrease in ^{18}F-FDG uptake at 2 cycles means residual tumor at the end of NAC and a high risk of early relapse.

Key Words: ^{18}F-FDG PET/CT; triple-negative breast cancer; neoadjuvant chemotherapy; metabolic response; prognosis

Triple-negative breast cancer (TNBC) accounts for 15% of invasive breast cancers and is characterized by the lack of estrogen and progesterone receptors and the absence of *HER2* overexpression (*1*). Patients with TNBC have a relatively poor outcome, with higher relapse rates than for other breast tumor types (*1*). However, these aggressive tumors have more intrinsic responsiveness to neoadjuvant chemotherapy (NAC) than estrogen receptor–positive tumors (*2*). Also, TNBC patients with a pathologic complete response

(pCR) after NAC have a good prognosis (*3*). In the M.D. Anderson series, TNBC patients who achieved a pCR (22%) had a 3-y overall survival of 94%, not significantly different from other tumor types (98%; $P = 0.24$), whereas those with residual tumor at surgery had a 3-y survival of only 68% (vs. 88% for other tumor types; $P = 0.0001$) (*3*). Therefore, obtaining a pCR is an important objective when TNBC patients are offered preoperative chemotherapy.

Metabolic evaluation with ^{18}F-FDG PET early in the course of treatment of some aggressive lymphomas, such as diffuse large B-cell lymphoma and Hodgkin disease, proved to be a powerful predictor of outcome (*4*). Many trials now use early ^{18}F-FDG assessment to switch lymphoma patients with an unfavorable response toward intensification of chemotherapy or alternative treatments (*5*). In breast cancer, several studies have evidenced a correlation between early changes in ^{18}F-FDG uptake after 1 or 2 courses of chemotherapy and the extent of pathologic response at completion of NAC (Rousseau et al. (*6*), Berriolo-Riedinger et al. (*7*), and Schwarz-Dose et al. (*8*), among others). However, the ability to implement PET as a surrogate marker for treatment efficacy in clinical practice remains unclear because of substantial heterogeneities across studies and also because breast cancer cannot be examined as a single entity (*9*). Breast cancer comprises different groups of tumors with different response rates to chemotherapy, different risks of relapse, different treatment options, and different prognoses. We have therefore suggested that the clinical aims of early ^{18}F-FDG monitoring and the criteria used to assess efficacy should be examined in specific subgroups (*9*).

This study investigated the value of interim PET in TNBC.

MATERIALS AND METHODS

Patients

During 30 mo, 20 consecutive patients with stage II or III breast carcinoma and a triple-negative phenotype underwent an

^{18}F-FDG PET/CT study before starting NAC and then after the second cycle. Four patients with distant metastases identified at initial staging were not included. After completion of NAC, all patients underwent breast-conserving surgery or mastectomy and dissection of axillary lymph nodes. The study was performed according to the guidelines of the institutional ethical committee.

NAC

Fourteen patients received 4 cycles of epirubicin (75 mg/m^2) plus cyclophosphamide (750 mg/m^2) administered every 3 wk, followed by 4 courses of docetaxel (100 mg/m^2). The last 6 included patients receiving epirubicin (75 mg/m^2) plus cyclophosphamide (1,200 mg/m^2) every 2 wk for 6 cycles (10).

^{18}F-FDG PET/CT

Patients fasted for 6 h. Blood glucose level had to be less than 7 mmol/L. ^{18}F-FDG (5 MBq/kg) was administered into the arm opposite to the breast tumor using a venous line to prevent extravasations. Imaging started 60 min after injection and was performed from mid-thigh level to the base of the skull with the arms raised. The Gemini XL PET/CT instrument combines a germanium oxyorthosilicate–based PET scanner and a 16-slice Brilliance CT scanner (Philips). CT data were acquired first (120 kV, 100 mAs, no contrast enhancement). PET emission data were acquired in a 3-dimensional mode, with 2 min per bed position, and reconstructed using a 3-dimensional row-action maximum-likelihood algorithm. The attenuation-corrected images were normalized for injected dose and body weight and converted into standardized uptake values (SUVs). The SUV was defined as (tracer concentration [kBq/mL])/(injected activity [kBq]/patient body weight [g]).

PET/CT images were interpreted by 2 nuclear medicine specialists masked to the patient's record. Images were displayed on the Extended Brilliance workstation (Philips). The SUV was measured by manually marking a circular region of interest in the 3 planes (coronal, sagittal, and axial) around the tumor (3-dimensional region of interest). The maximum SUV (SUVmax within the region of interest) was used for the study analysis.

The change in SUV after 2 cycles of chemotherapy was expressed as ΔSUVmax (%) = 100 × (second-cycle SUVmax − baseline SUVmax)/baseline SUVmax.

Tumor Histology and Immunohistochemistry Analysis

Breast cancer was diagnosed using core-needle biopsy. Histologic grade was determined using the modified Scarff–Bloom–Richardson grading for invasive carcinoma.

Tumors were defined as triple-negative on the basis of immunohistochemical test results performed on formalin-fixed, paraffin-embedded tissues, using specific antibodies and an automated immunostainer (XT Immunostainer; Ventana). Tumors were considered to overexpress *HER2* if more than 30% of invasive tumor cells showed definite membrane staining resulting in a so-called fishnet appearance; control by FISH (fluorescence in situ hybridization) or SISH (silver enhanced in situ hybridization) was done for ambiguous cases. Tumors were considered estrogen receptor– and progesterone receptor–negative if there was less than 10% staining.

Pathology Assessment at Completion of NAC

pCR was defined as no evidence of residual invasive cancer, both in breast tissues and in lymph nodes (11,12). The absence of carcinoma in situ was not mandatory to define pCR (11).

Disease-Free Survival (DFS)

DFS was calculated from the time of surgery. Events included local, regional, or distant recurrences or death, whichever occurred first.

Statistical Analysis

Analyses were performed using R 2.12.0 statistical software (The R Foundation for Statistical Computing).

RESULTS

Patients and tumor characteristics of the 20 TNBC patients included in this study are summarized in Table 1.

Pathologic Response

At completion of NAC, breast-conserving surgery was performed in 6 patients and mastectomy in 14 patients. All patients had axillary lymph node dissection. Histopathol-

TABLE 1
Overall Characteristics of TNBC Patients

Characteristic	No. of patients (n = 20)
Tumor classification	
T1	0
T2	7 (35)
T3	6 (30)
T4	7 (35)
Lymph node classification	
N0	7 (35)
N1	7 (35)
N2	3 (15)
N3	3 (15)
AJCC clinical stage	
IIA	3 (15)
IIB	6 (30)
IIIA	3 (15)
IIIB	5 (25)
IIIC	3 (15)
Tumor type	
Invasive ductal, no special type	18 (90)
Metaplastic	2 (10)
Lobular	0
Grade	
1	0
2	5 (25)
3	15 (75)
Chemotherapy	
EC-T	14 (70)
SIM	6 (30)
Surgery	
Breast-conserving	6 (30)
Mastectomy	14 (70)
Pathologic response	
pCR	6 (30)
Non-pCR	14 (70)

Data in parentheses are percentages. Mean age was 51.6 y, and age range was 22–78 y.

AJCC = American Joint Committee on Cancer; EC-T = sequential regimen of 4 cycles of epirubicin (75 mg/m^2) plus cyclophosphamide (750 mg/m^2), followed by 4 courses of docetaxel (100 mg/m^2); SIM = intensified regimen of epirubicin (75 mg/m^2) plus cyclophosphamide (1,200 mg/m^2) for 6 cycles.

ogy revealed pCR in 6 patients (30%), whereas 14 patients (70%) had residual disease (non-pCR).

Change in SUV and Pathologic Response

Table 2 shows individual data for each patient including baseline PET and interim PET SUV results, ΔSUV, results of surgery, and disease outcome.

At baseline, SUVmax values ranged between 1.5 and 27.0 (mean, 11.2). After 2 courses of chemotherapy, SUVmax ranged between 1.1 and 30.6 (mean, 5.8).

The mean ΔSUVmax (ΔSUV) between initial and interim PET was −45% (range, −91% to +13%). The mean ΔSUV was −73% in patients who achieved a pCR versus −33% in patients who did not ($P = 0.0008$ with t test). Figure 1 shows initial and interim ^{18}F-FDG PET/CT results in a patient who had a pCR. The ability of ΔSUV to predict pathology findings (non-pCR vs. pCR) was derived by computing the area under the receiver-operating-characteristic curve, yielding an area under the curve of 0.881 (Fig. 2).

No correlation was found between histopathologic response and SUVmax at baseline ($P = 0.22$; Wilcoxon rank sum test) or after the second cycle of chemotherapy ($P = 0.30$); only the change in SUV was predictive.

Change in SUV and DFS

The mean follow-up after surgery was 20 mo (range, 7–37 mo). The 2-y DFS was 77%. Four patients experienced early relapse; 2 of them died (Table 2).

No correlation was found between relapse events and SUVmax at baseline ($P = 0.54$; Wilcoxon rank sum test) or after the second cycle of chemotherapy ($P = 0.42$).

Screening for different cutoffs identified a cutoff of a 42% decrease in SUVmax as the best predictor of DFS. Figure 3 shows the Kaplan–Meier DFS curves for metabolic responders (≥42% decrease) and nonresponders (<42% decrease). None of the 11 metabolic responders relapsed, including 5 patients who did not achieve a pCR.

Choice of Cutoff

Figure 4 shows the distributions of pCR, non-pCR, and relapses, according to the decrease in SUVmax at 2 cycles. The cutoff of 42% is drawn on the graph. With this division, there were 11 metabolic responders and 9 nonresponders. Residual tumor (non-pCR) was found in 100% of nonreponders versus 45% of responders ($P = 0.014$; Fisher exact test). The sensitivity for identification of non-pCR was 64% (9/14), and specificity was 100% (6/6). The relapse rate was 44% for nonresponders and 0% for responders ($P = 0.024$; log rank).

When using a cutoff of a 50% decrease in SUVmax, sensitivity for non-pCR increased (79%). However, the positive predictive value for relapse decreased (36%).

DISCUSSION

In this prospective study, an interim ^{18}F-FDG PET examination after 2 cycles of NAC was predictive of patho-

TABLE 2
Individual Outcomes for 20 Patients with TNBC

Patient no.	Age (y)	Histology	Grade	Chemotherapy regimen	Stage	Basal SUVmax	SUVmax after 2 cycles	Δ SUV	Surgery	Pathologic response	Relapse
1	53	IDC	3	EC-T	IIIB	23.3	3.7	−84%	Mastectomy	pCR	No
2	40	IDC	3	EC-T	IIA	22.7	9.3	−59%	BCS	pCR	No
3	45	MC	3	SIM	IIB	15.9	1.5	−91%	Mastectomy	pCR	No
4	60	IDC	3	SIM	IIIB	6.8	1.3	−81%	Mastectomy	pCR	No
5	52	IDC	3	SIM	IIIB	14.8	4.7	−68%	Mastectomy	pCR	No
6	61	IDC	3	EC-T	IIIC	6.0	2.8	−53%	Mastectomy	pCR	No
7	43	IDC	3	EC-T	IIIC	9.7	6.9	−29%	Mastectomy	Non-pCR	Local/distant*
8	78	IDC	2	EC-T	IIA	1.5	1.1	−27%	BCS	Non-pCR	No
9	46	IDC	3	EC-T	IIA	6.8	2.0	−71%	BCS	Non-pCR	No
10	77	IDC	2	EC-T	IIIB	5.3	2.8	−47%	Mastectomy	Non-pCR	No
11	38	IDC	3	EC-T	IIIB	27.0	30.6	+13%	Mastectomy	Non-pCR	No
12	38	IDC	3	EC-T	IIB	15.2	1.5	−90%	BCS	Non-pCR	No
13	56	MC	3	EC-T	IIB	6.2	4.8	−23%	Mastectomy	Non-pCR	No
14	44	IDC	3	EC-T	IIB	7.2	6.2	−14%	Mastectomy	Non-pCR	No
15	68	IDC	2	EC-T	IIB	2.2	1.6	−27%	BCS	Non-pCR	Distant*
16	50	IDC	3	EC-T	IIIA	14.1	5.3	−62%	Mastectomy	Non-pCR	No
17	64	IDC	2	EC-T	IIB	16.7	9.6	−43%	Mastectomy	Non-pCR	No
18	27	IDC	3	SIM	IIIA	9.2	5.5	−40%	BCS	Non-pCR	Regional
19	33	IDC	2	SIM	IIIA	6.4	6.4	0%	Mastectomy	Non-pCR	No
20	59	IDC	3	SIM	IIIC	7.6	7.8	+3%	Mastectomy	Non-pCR	Local

*These 2 patients died.

IDC = invasive ductal carcinoma; EC-T = sequential regimen of 4 cycles of epirubicin (75 mg/m²) plus cyclophosphamide (750 mg/m²), followed by 4 courses of docetaxel (100 mg/m²); MC = metaplastic carcinoma; SIM = intensified regimen of epirubicin (75 mg/m²) plus cyclophosphamide (1,200 mg/m²) for 6 cycles; BCS = breast-conserving surgery.

FIGURE 1. A 53-y-old patient with TNBC (patient 1; Table 2). Triple-negative tumor was 80-mm grade 3 invasive ductal carcinoma of right breast, invading areola (T4N1M0; stage IIIB). (A and B) Transaxial CT and fused PET/CT images of primary tumor at baseline. (C and D) Corresponding images after 2 courses of NAC. At baseline, SUVmax of 23.3 is measured at breast tumor level. After 2 courses of chemotherapy, there is residual uptake, with SUVmax of 3.7 (ΔSUV, −84%). At completion of chemotherapy (after 2 additional courses of epirubicin [75 mg/m^2] plus cyclophosphamide [750 mg/m^2] and 4 courses of docetaxel [100 mg/m^2]), breast mastectomy shows pCR, with absence of residual tumor cells in breast and no cancer cells in 9 lymph nodes removed at axillary dissection.

FIGURE 2. Capacity of ΔSUV at 2 cycles to predict residual tumor (non-pCR) at surgery after completion of NAC, derived by the area under the receiver-operating-characteristic curve (AUC).

logic response (Fig. 2) and DFS (Fig. 3) in patients with TNBC, an aggressive subtype of breast cancer.

At completion of NAC, residual tumor was found in 70% and pCR in 30% of patients, which is similar to other reports (1–3,13). The mean ΔSUV at 2 cycles was −33% in patients with residual tumor versus −73% in those who achieved a pCR ($P = 0.0008$).

Four patients (20%) presented early relapse. All 4 patients had little modification of SUV (mean ΔSUVmax, −23%). Threshold screening identified a cutoff of a 42% decrease in SUVmax as the best predictor of outcomes. With this cutoff, 9 of 20 patients were nonresponders. In them, the risk of a non-pCR was 100% (vs. 45% in responders; $P = 0.014$), and the risk of early relapse was 44% (vs. 0%; log rank $P = 0.024$).

A less stringent cutoff to define nonresponders (<50% decrease in SUVmax) offered higher sensitivity in identifying non-pCR cases. However, the predictive value for relapse decreased. When interim ^{18}F-FDG PET is used as a surrogate for poor response to NAC, a stringent cutoff is needed to avoid a change in treatment when it might benefit. This 42% cutoff needs to be validated using an independent dataset.

Poor metabolic response at 2 cycles (<42% decrease in SUV) was more predictive of relapse (4/9) than was a non-pCR at completion of NAC (4/14). Importantly, early assessment might offer an opportunity to change strategy in the case of inefficacy.

Novel treatment strategies are being investigated. We reported a 10-y DFS rate of 76% in TNBC patients using cyclophosphamide dose intensification (10). Several ongoing studies involve new cytotoxic agents or targeted thera-


FIGURE 3. Kaplan–Meier DFS curves for metabolic responders (≥42% decrease) and metabolic nonresponders (<42% decrease).

FIGURE 4. Pathology results and relapses according to decrease in SUVmax after 2 cycles of chemotherapy. Graph shows distribution of pCR (blue triangles) and non-pCR (circles). Red-filled circles correspond to relapses. Open circles correspond to non-pCR patients who did not relapse.

are available online only at http://jnm.snmjournals.org). We did not exclude these patients to avoid potential bias. Nevertheless, exclusion of these 2 patients would not change the findings of this study. The mean ΔSUV at 2 cycles was -34% in patients with residual tumor versus -73% in those who achieved a pCR ($P = 0.003$). The risk of early relapse was 43% (3/7) in nonresponders vs 0% in the 11 responders ($P = 0.025$) (Supplemental Fig. 2) using a cutoff of a 42% decrease in SUVmax.

Regarding alternative techniques with potential for early evaluation of response, there are some encouraging data with MRI (*19,20*).

Our single-institution study included 20 women with triple-negative tumor referred for NAC (usually when >3 cm). Although the number of patients is small, and follow-up relatively short (mean, 20 mo), the findings clearly point to the excellent predictive power of ΔSUV to early identify poor responders to the planned chemotherapy. A multiinstitutional study should be performed to validate these findings before interim PET is used as a surrogate marker in clinical trials involving novel therapeutic strategies.

CONCLUSION

In patients with TNBC, the change in ^{18}F-FDG tumor uptake after 2 cycles of NAC offers powerful stratification of patient outcomes. It early identifies poor metabolic responders who would end up with residual tumor at the end of the planned NAC regimen and who have a high risk of early relapse.

DISCLOSURE STATEMENT

ACKNOWLEDGMENTS

pies (*14*). Inherent defects in DNA repair make TNBC a rational target for therapy based on polymerase (adenosine diphosphate-ribose) polymerase (PARP) (*1*); PARP inhibitors, with or without combination with platinum salts, are now at the forefront of clinical research in TNBC patients (*15*).

Triple-negative tumors are recognized to be ^{18}F-FDG–avid (*16–18*). High SUV at baseline facilitates metabolic assessment with PET. Baseline values were low in 2 of our patients (patients 8 and 15), rendering metabolic evaluation more difficult (Supplemental Fig. 1; supplemental materials

REFERENCES

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med.* 2010;363:1938–1948.
2. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res.* 2007;13:2329–2334.
3. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol.* 2008;26:1275–1281.
4. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[^{18}F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to interna-

tional prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. *J Clin Oncol.* 2007;25:3746–3752.

5. Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. *Br J Haematol.* 2011;152:551–560.

6. Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. *J Clin Oncol.* 2006;24:5366–5372.

7. Berriolo-Riedinger A, Touzery C, Riedinger J, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. *Eur J Nucl Med Mol Imaging.* 2007;34:1915–1924.

8. Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. *J Clin Oncol.* 2009;27: 535–541.

9. Groheux D, Giacchetti S, Espié M, Rubello D, Moretti J, Hindié E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. *Eur J Nucl Med Mol Imaging.* 2011;38:419–425.

10. Lehmann-Che J, André F, Desmedt C, et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. *Oncologist.* 2010;15:246–252.

11. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. *J Clin Oncol.* 2008;26:814–819.

12. Edge SB, Byrd DR, Compton CC, eds. *AJCC Cancer Staging Manual.* 7th ed. New York, NY: Springer; 2010.

13. Pierga J, Delaloge S, Espié M, et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. *Breast Cancer Res Treat.* 2010; 122:429–437.

14. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. *Breast Cancer Res Treat.* 2010;121:261–271.

15. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. *N Engl J Med.* 2011;364:205–214.

16. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. *Cancer.* 2008;112:995–1000.

17. Groheux D, Giacchetti S, Moretti J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. *Eur J Nucl Med Mol Imaging.* 2011;38:426–435.

18. Specht JM, Kurland BF, Montgomery SK, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. *Clin Cancer Res.* 2010;16:2803–2810.

19. Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. *J Clin Oncol.* 2011;29:660–666.

20. Kawashima H, Inokuchi M, Furukawa H, Kitamura S. Triple-negative breast cancer. Are the imaging findings different between responders and non-responders to neoadjuvant chemotherapy? *Acad Radiol.* 2011;18:963–969.